Technology around cell and gene therapy is progressing, with a simplified, cost-efficient improvement to today’s cumbersome viral vector delivery pathway likely in a matter of years.
GE Healthcare’s strategy manager for cell and gene therapy and board member of the Alliance for Regenerative Medicine, Phil...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?